The enhanced lncSNHG5 and CCL2/CCL5 may serve as potential novel diagnostic markers, and RS102895, maraviroc or cenicriviroc, and inhibitors of CCR2 and/or CCR5, may be potential molecules to prevent lung metastasis in BC patients. Here, CCL5 is linked to breast cancer.